Efficacy and safety of doripenem (3g/day) in the treatment of severe/refractory respiratory infections

Efficacy and safety of doripenem (3g/day) in the treatment of severe/refractory respiratory infections - Efficacy and safety of doripenem (3g/day) in the treatment of severe/refractory respiratory infections

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012685

Enrollment

Registered

2013-12-25

Start date

2013-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe/refractory respiratory infections

Interventions

Doripenem (3g/day) is given intravenously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients 20 years of age and older 2.Patients with severe/very severe pneumonia according to the Japan Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia or Healthcare-associated Pneumonia in Adults .

Exclusion criteria

Exclusion criteria: 1.Patients who had been treated with doripenem 2.Contraindication for doripenem 3.Liver insufficiency (elevated levels of AST/ALT more than 5 times of the upper limits) 4.Renal insufficiency (elevated levels of BUN/creatinine more than 2 times of the upper limits) 5.Patients anticipating being susceptive of convulsion after brain disorders 6.Patients deemed ineligible by the attending physicians for various reasons.

Design outcomes

Primary

Measure	Time frame
Clinical efficacy at the end of doripenem (3g/day) administration	—

Countries

Japan

Contacts

Public ContactToshinori Kawanami

University of Occupational and Environmental Health, Japan Department of Respiratory Medicine

namihei@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026